Value-Based Pricing
Value-Based Pricing (VBP) aligns the price of a treatment with the value it provides to patients, healthcare systems, and society. Across multiple indications, a single price may not accurately reflect a medicine’s value, Indication-Based Pricing (IBP) allows different prices to be set for different indications.
New: Operationalising Value Based Pricing
11 August 2011
To date, the UK Government has not been specific about how VBP will be implemented, but has indicated that calculations of value will extend beyond the…
Workshop on Responding to Value-Based Pricing
6 June 2011
Register now for our workshop on ‘value-based pricing’, how it relates to risk-sharing and patient access schemes and what approaches might make the most sense.
Value-Based Pricing: OHE Comments
23 March 2011
In December 2010, the UK Department of Health released a consultation document to elicit comments on ‘proposals for a new value-based system of pricing medicines which…
Update: Value-Based Pricing in the UK
11 January 2011
Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For…
Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
1 August 2011
Recent reforms to the National Health Service (NHS) in England include important changes in the regulation of prices for new medicines. From January 2014, the existing…
Value Based Pricing in the UK
7 September 2010
Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances. In a recent article…
Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?
1 October 2009
In this Briefing, five leading European experts in health economics provide a comprehensive international review of changes in health economic evaluation and the reasons for them. …